Cardiovascular Health

In light of misrepresented statistics and overstated fears about statin-related adverse events, here are 3 of the biggest myths your patients may have heard about these life-saving medications-and the facts

Labels of prescription testosterone products must now include information about possible cardiovascular and stroke risks associated with their use.

Almost all women and seniors with atrial fibrillation should be receiving blood thinners, advises a new analysis of updated clinical practice guidelines.

Casting doubt on previous conjectures, a new study suggests that statins do not protect patients against Parkinson's disease.

Even short-term treatment with nonsteroidal anti-inflammatory drugs is associated with significant increases in bleeding and cardiovascular event risk in patients receiving antithrombotic therapy after a heart attack.

Is it possible for Twitter to predict a community's level of heart disease?

Simple physical activity such as moving around the house can have a substantial effect on seniors' cardiovascular health.

The risk of heart attack is 8.5 times higher in the 2 hours following bursts of intense anger, suggests research from the University of Sydney.

While statins can effectively reduce cholesterol levels, a new study has found that the medications leave much to be desired in terms of substantially improving cardiovascular symptoms.

Teva Pharmaceutical Industries recently launched generic versions of Sanofi's enoxaparin sodium injection (Lovenox) and Pfizer's linezolid injection (Zyvox).

The clinical risk calculators incorporated into dyslipidemia treatment guidelines may overestimate a patient's risk of experiencing a cardiovascular event.

A paper from a pair of physicists may reveal significant new information about the causes of atrial fibrillation and help to make cardiac ablations a more effective treatment for the condition.

Gastroesophageal reflux disease and atrial fibrillation are 2 of the most significant health concerns in the United States, and researchers suspect a link between them.

Prescribing methods for a newer atrial fibrillation agent require more monitoring to improve patient safety in community hospitals.

Several studies have reported that controlling blood pressure with medication improves cardiovascular outcomes.

The FDA has granted 510(k) clearance to Silk Road Medical's Enroute Transcarotid Neuroprotection System (TNS), a first-in-class device to restore normal blood flow to narrowed carotid arteries during carotid angioplasty and stenting.

Daiichi Sankyo today announced the US launch of edoxaban, a once-daily anti-clotting agent indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

New research published in the British Medical Journal has answered some of the most basic questions about treating hypertension.

Despite having adequate knowledge on cardiovascular risk factors, pharmacists and other health care professionals showed significant increases in systemic arterial hypertension and excessive weight gain across a 20-year study.

One in three people say they would risk living a shorter life instead of taking a daily pill to prevent cardiovascular disease, according to new research inCirculation: Cardiovascular Quality and Outcomes.

What's keeping insomniacs awake at night might also be raising their blood pressure.

Reducing elevated blood pressure during pregnancy is safe for the expectant mother and her child.

A primary goal of managing atrial fibrillation is relief of symptoms that include dizziness, fatigue, palpitations, shortness of breath, and chest pain. Yet, it is symptomless in up to one-third of patients.

Women diagnosed with polycystic ovary syndrome are more likely to develop heart disease, diabetes, and other chronic conditions than those without the hormone disorder.

Improved care for HIV-infected patients within the Kaiser Permanente system has essentially reversed their previously reported increased heart attack risk.

Avocados may help reduce low-density lipoprotein cholesterol.

Use of anticoagulants in atrial fibrillation patients remains unacceptably low, with some estimates showing that only half of patients receive anticoagulants as indicated by current treatment guidelines.

One of the most common questions from prescribers that I have answered in the past year concerns how to convert from 1 anticoagulant to anothe

Not every patient requires an aspirin a day.

Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals' rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug's safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.